3SBio Inc. is an investment holding company primarily engaged in the biotechnology and drugs industries. Headquartered in Shenyang, China, the company was founded in 1993 and has expanded its operations into Sri Lanka, the Dominican Republic, and Thailand. Through its various holding companies, 3SBio Inc. is involved in research and development, manufacturing, and the distribution of biopharmaceuticals in these regions and across the People’s Republic of China.
3SBio Inc. manufactures and distributes a wide range of biopharmaceuticals through its various holding companies. This includes a number of drugs for the treatment of breast cancer, anaemia, vomiting, and thrombosis disorders. It also engages in trading, project management and consultation, and technology services. 3SBio Inc. has collaboration agreements with companies such as AstraZeneca, Lilly, Tory, Samsung Bioepis, and INV.
The company has developed seven approved biopharmaceuticals, with several innovative product lines under investigation, including 22 National New Drugs. It has promising product candidates in the areas of oncology, rheumatology, nephrology, and metabolism. In addition, the company operates advanced production facilities that cover monoclonal antibodies, mammalian cells, bacteria, and chemically synthesized molecules. 3SBio Inc. is listed on the Hong Kong Stock Exchange under the ticker 1530.HK.
Add the 3SBio Inc. stock ticker to your eToro watchlist for all the latest news and price updates.